[144] Disc Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 24,962 shares of common stock, with an aggregate market value of $1,473,506.86, to be sold through Merrill Lynch One Bryant Park, New York on Nasdaq with an approximate sale date of 08/13/2025. The filing states the shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date.

The form also lists multiple sale transactions by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. during July and August 2025, including a sale of 53,215 shares on 07/23/2025 for $3,244,656.91. The filing reports 34,765,581 shares outstanding for the issuer. No signature date or additional issuer relationship details are provided in the extract.

Positive

• None.

Negative

• Proposed sale of 24,962 common shares valued at $1,473,506.86 to be executed via Merrill Lynch on 08/13/2025
• Multiple large sales by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. in July-August 2025, including 53,215 shares sold on 07/23/2025 for $3,244,656.91
• Filing extract does not provide relationship to issuer or signature date in the provided content

Insights

Securities Analyst

TL;DR Form 144 notifies a planned sale of 24,962 shares and discloses recent large disposals by Atlas Venture funds.

The filing explicitly reports a proposed sale of 24,962 common shares valued at $1,473,506.86, to be executed via Merrill Lynch on Nasdaq on 08/13/2025. It confirms those shares were acquired in a private placement on 05/01/2020 and paid in cash. The document also lists several recent sales by Atlas Venture entities in July and August 2025, including a 53,215-share sale on 07/23/2025 for $3,244,656.91. For investors, the filing provides clear transaction and timing details but contains no commentary on intent or relationship to management in the provided excerpt.

Risk Analyst

TL;DR Multiple sizable stock disposals are reported; filing provides transactional transparency but implies concentrated selling activity.

The extract documents multiple sizable sales by Atlas Venture Fund X and Atlas Venture Opportunity Fund I across July and August 2025, with individual transactions and gross proceeds listed (for example, 53,215 shares for $3,244,656.91 on 07/23/2025). The proposed sale of 24,962 shares (aggregate value $1.47M) is scheduled for 08/13/2025. These data points are material disclosures of selling activity in the issuer's stock in the period covered by the filing excerpt. The filing excerpt does not include investor communications, relationships, or explanatory remarks that would clarify motives or broader liquidity plans.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch One Bryant Park New York NY 10036	24962	1473506.86	34765581	08/13/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2020	Private Placement	Issuer			24962	05/01/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/18/2025	1184	72375.20
Atlas Venture Opportunity Fund I, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/18/2025	664	40588.80
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/23/2025	53215	3244656.91
Atlas Venture Opportunity Fund I, LP. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/23/2025	29837	1819239.47
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/24/2025	23245	1421824.59
Atlas Venture Opportunity Fund I, LP. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/24/2025	13033	797188.21
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/30/2025	15146	924472.46
Atlas Venture Opportunity Fund I, LP. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/30/2025	8492	518329.60
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	08/05/2025	705	42969.75
Atlas Venture Opportunity Fund I, LP. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	08/05/2025	395	24075.25

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Disc Medicine (IRON) Form 144 report?

The filing reports a proposed sale of 24,962 common shares with aggregate market value $1,473,506.86, to be sold via Merrill Lynch on Nasdaq on 08/13/2025.

When and how were the shares being sold on Form 144 acquired?

The shares were acquired in a private placement from the issuer on 05/01/2020 and payment was made in cash on 05/01/2020.

How many shares outstanding does the filing list for the issuer?

The filing lists 34,765,581 shares outstanding for the issuer.

Does the filing disclose other recent sales by related parties?

Yes. The filing lists multiple sales by Atlas Venture entities in July-August 2025, for example 53,215 shares sold on 07/23/2025 for $3,244,656.91.

Who is the broker handling the proposed sale?

The broker named in the filing is Merrill Lynch One Bryant Park, New York, NY 10036.